Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Articles|June 2, 2010
- Pharmaceutical Technology-06-02-2010
- Volume 34
- Issue 6
Pharmaceutical Technology, June 2010 Issue (PDF)
Excipients Step into the Spotlight
Advertisement
Articles in this issue
over 16 years ago
Anniversary Seasonover 16 years ago
Outsourcing Clinical Trial Development and Materialsover 16 years ago
Leveling the Compliance Playing Fieldover 16 years ago
Excipients Step into the Spotlightover 16 years ago
EU Debt Crisis Adds Uncertaintyover 16 years ago
Puerto Rico Builds a Foundation for Biopharmaceuticalsover 16 years ago
Even Packaging Can Multitaskover 16 years ago
Securing the Supply Chainover 16 years ago
A Q&A with Uwe Ross of Binderover 16 years ago
Making a DifferenceAdvertisement
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
3
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
4
Our Biggest Takeaways From AAPS PharmSci 360
5